FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2613210669> ?p ?o ?g. }

• W2613210669 endingPage "e170580" @default.
• W2613210669 startingPage "e170580" @default.
• W2613210669 abstract "Minimal residual disease (MRD) refers to the presence of disease in cases deemed to be in complete remission by conventional pathologic analysis. Assessing the association of MRD status following induction therapy in patients with acute lymphoblastic leukemia (ALL) with relapse and mortality may improve the efficiency of clinical trials and accelerate drug development.To quantify the relationships between event-free survival (EFS) and overall survival (OS) with MRD status in pediatric and adult ALL using publications of clinical trials and other databases.Clinical studies in ALL identified via searches of PubMed, MEDLINE, and clinicaltrials.gov.Our search and study screening process adhered to the PRISMA Guidelines. Studies that addressed EFS or OS by MRD status in patients with ALL were included; reviews, abstracts, and studies with fewer than 30 patients or insufficient MRD description were excluded.Study sample size, patient age, follow-up time, timing of MRD assessment (postinduction or consolidation), MRD detection method, phenotype/genotype (B cell, T cell, Philadelphia chromosome), and EFS and OS. Searches of PubMed and MEDLINE identified 566 articles. A parallel search on clinicaltrials.gov found 67 closed trials and 62 open trials as of 2014. Merging results of 2 independent searches and applying exclusions gave 39 publications in 3 arms of patient populations (adult, pediatric, and mixed). We performed separate meta-analyses for each of these 3 subpopulations.The 39 publications comprised 13 637 patients: 16 adult studies (2076 patients), 20 pediatric (11 249 patients), and 3 mixed (312 patients). The EFS hazard ratio (HR) for achieving MRD negativity is 0.23 (95% Bayesian credible interval [BCI] 0.18-0.28) for pediatric patients and 0.28 (95% BCI, 0.24-0.33) for adults. The respective HRs in OS are 0.28 (95% BCI, 0.19-0.41) and 0.28 (95% BCI, 0.20-0.39). The effect was similar across all subgroups and covariates.The value of having achieved MRD negativity is substantial in both pediatric and adult patients with ALL. These results are consistent across therapies, methods of and times of MRD assessment, cutoff levels, and disease subtypes. Minimal residual disease status warrants consideration as an early measure of disease response for evaluating new therapies, improving the efficiency of clinical trials, accelerating drug development, and for regulatory approval. A caveat is that an accelerated approval of a particular new drug using an intermediate end point, such as MRD, would require confirmation using traditional efficacy end points." @default.
• W2613210669 created "2017-05-19" @default.
• W2613210669 creator A5013754928 @default.
• W2613210669 creator A5019914745 @default.
• W2613210669 creator A5024610298 @default.
• W2613210669 creator A5030122856 @default.
• W2613210669 creator A5048308941 @default.
• W2613210669 creator A5061265799 @default.
• W2613210669 creator A5063454708 @default.
• W2613210669 creator A5073571977 @default.
• W2613210669 creator A5085593914 @default.
• W2613210669 creator A5089541690 @default.
• W2613210669 date "2017-07-13" @default.
• W2613210669 modified "2023-10-18" @default.
• W2613210669 title "Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia" @default.
• W2613210669 cites W11202050 @default.
• W2613210669 cites W1643112662 @default.
• W2613210669 cites W1676308378 @default.
• W2613210669 cites W1685744202 @default.
• W2613210669 cites W1937081953 @default.
• W2613210669 cites W1967348190 @default.
• W2613210669 cites W1975886849 @default.
• W2613210669 cites W1982967337 @default.
• W2613210669 cites W1984684983 @default.
• W2613210669 cites W1984877560 @default.
• W2613210669 cites W1987538151 @default.
• W2613210669 cites W1998660089 @default.
• W2613210669 cites W2004363114 @default.
• W2613210669 cites W2013779251 @default.
• W2613210669 cites W2014804837 @default.
• W2613210669 cites W2021312489 @default.
• W2613210669 cites W2024540195 @default.
• W2613210669 cites W2031803874 @default.
• W2613210669 cites W2034592954 @default.
• W2613210669 cites W2039149330 @default.
• W2613210669 cites W2042576462 @default.
• W2613210669 cites W2044477012 @default.
• W2613210669 cites W2049000194 @default.
• W2613210669 cites W2049665361 @default.
• W2613210669 cites W2050152294 @default.
• W2613210669 cites W2052505636 @default.
• W2613210669 cites W2058885398 @default.
• W2613210669 cites W2071206691 @default.
• W2613210669 cites W2071780943 @default.
• W2613210669 cites W2075139424 @default.
• W2613210669 cites W2075894019 @default.
• W2613210669 cites W2084781910 @default.
• W2613210669 cites W2089445567 @default.
• W2613210669 cites W2091650771 @default.
• W2613210669 cites W2094615848 @default.
• W2613210669 cites W2094818544 @default.
• W2613210669 cites W2097732803 @default.
• W2613210669 cites W2097799776 @default.
• W2613210669 cites W2100025372 @default.
• W2613210669 cites W2109388187 @default.
• W2613210669 cites W2110661347 @default.
• W2613210669 cites W2118241155 @default.
• W2613210669 cites W2124174337 @default.
• W2613210669 cites W2125233997 @default.
• W2613210669 cites W2128497441 @default.
• W2613210669 cites W2132827894 @default.
• W2613210669 cites W2140864225 @default.
• W2613210669 cites W2141539055 @default.
• W2613210669 cites W2143939343 @default.
• W2613210669 cites W2147572934 @default.
• W2613210669 cites W2148631711 @default.
• W2613210669 cites W2154946763 @default.
• W2613210669 cites W2161996216 @default.
• W2613210669 cites W2163926478 @default.
• W2613210669 cites W2168438358 @default.
• W2613210669 cites W2169269721 @default.
• W2613210669 cites W2283816551 @default.
• W2613210669 cites W3022433738 @default.
• W2613210669 cites W3022903699 @default.
• W2613210669 cites W4232666751 @default.
• W2613210669 cites W4243761960 @default.
• W2613210669 cites W1861578065 @default.
• W2613210669 doi "https://doi.org/10.1001/jamaoncol.2017.0580" @default.
• W2613210669 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5824235" @default.
• W2613210669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28494052" @default.
• W2613210669 hasPublicationYear "2017" @default.
• W2613210669 type Work @default.
• W2613210669 sameAs 2613210669 @default.
• W2613210669 citedByCount "350" @default.
• W2613210669 countsByYear W26132106692017 @default.
• W2613210669 countsByYear W26132106692018 @default.
• W2613210669 countsByYear W26132106692019 @default.
• W2613210669 countsByYear W26132106692020 @default.
• W2613210669 countsByYear W26132106692021 @default.
• W2613210669 countsByYear W26132106692022 @default.
• W2613210669 countsByYear W26132106692023 @default.
• W2613210669 crossrefType "journal-article" @default.
• W2613210669 hasAuthorship W2613210669A5013754928 @default.
• W2613210669 hasAuthorship W2613210669A5019914745 @default.
• W2613210669 hasAuthorship W2613210669A5024610298 @default.
• W2613210669 hasAuthorship W2613210669A5030122856 @default.
• W2613210669 hasAuthorship W2613210669A5048308941 @default.
• W2613210669 hasAuthorship W2613210669A5061265799 @default.

• next